Krawczyk Z
Acta Biochim Pol. 1982;29(3-4):259-73.
Ledakrin, 1-nitro-9-[3'-(N,N'-dimethyl)aminopropyl]aminoacridine administered intraperitoneally at a dose up to 20 mg/kg into sham operated and partially hepatectomized rats inhibited RNA polymerase B activity in the isolated liver nuclei. The average chain length of the in vitro transcript was reduced while the number of elongating RNA polymerase B molecules was not changed after Ledakrin treatment. The drug inhibited RNA polymerase B activity in 18 hour regenerating liver to a much greater extent than in control liver. However, one molecule of tritium-labelled Ledakrin was bound with the same number of base pairs of DNA both in normal and regenerating liver. About 60 to 70% of the label was found to form labile complexes with DNA and could be liberated on thermal, alkaline or acidic denaturation of DNA. The remaining label seems to be covalently bound to DNA. The drug induced "cross-links" between the two strands of rat liver DNA in vivo. DNA from the liver nuclei unable to synthesize RNA due to Ledakrin treatment, retained the template activity against E. coli RNA polymerase. The presented results point to a limited preference of Ledakrin to bind to the transcriptionally active regions of chromatin.
利达克林,即1-硝基-9-[3'-(N,N'-二甲基)氨基丙基]氨基吖啶,以高达20毫克/千克的剂量腹腔注射到假手术和部分肝切除的大鼠体内,可抑制离体肝细胞核中的RNA聚合酶B活性。利达克林处理后,体外转录本的平均链长缩短,而正在延伸的RNA聚合酶B分子数量未变。该药物对18小时再生肝中RNA聚合酶B活性的抑制程度远大于对照肝。然而,在正常肝和再生肝中,一分子氚标记的利达克林与相同数量碱基对的DNA结合。发现约60%至70%的标记物与DNA形成不稳定复合物,在DNA热变性、碱变性或酸变性时可释放出来。其余标记物似乎与DNA共价结合。该药物在体内诱导大鼠肝DNA两条链之间形成“交联”。因利达克林处理而无法合成RNA的肝细胞核中的DNA,对大肠杆菌RNA聚合酶仍保留模板活性。所呈现的结果表明,利达克林对染色质转录活性区域的结合偏好有限。